Lesson
Start With the Polymer
Sickle cell disease begins with inherited hemoglobin variants, but clinical disease emerges through deoxygenation, HbS polymerization, membrane injury, hemolysis, adhesion, inflammation, and microvascular obstruction.
- HbS
- Polymerization
- Hemolysis
- Vaso-occlusion
- HbF
- Genotype
Fibers distort the red cell and damage its membrane
Sickled cells, endothelium, platelets, and leukocytes obstruct microvessels
Anemia, bilirubin, nitric oxide biology, and vascular stress emerge
More HbF reduces participation in HbS polymer formation
Read genotype without predicting destiny
HbSS, HbS beta-zero thalassemia, HbSC, HbS beta-plus thalassemia, and other combinations differ in average risk. Genotype, HbF, coinherited alpha thalassemia, treatment, environment, and prior complications all shape phenotype.
Follow deoxygenated HbS
When oxygen tension falls, HbS molecules can assemble into polymers. Repeated cycles damage the membrane, reduce deformability, increase dehydration, and shorten red cell survival. Acidosis, infection, dehydration, cold stress, and hypoxemia can intensify risk.
Connect hemolysis and occlusion
Extravascular and intravascular hemolysis produce chronic anemia, reticulocytosis, bilirubin elevation, gallstones, and vascular effects. Adhesion among red cells, leukocytes, platelets, and endothelium contributes to intermittent and persistent ischemic injury.
Interpret laboratory patterns in context
Use CBC, reticulocytes, bilirubin, LDH, haptoglobin, smear, and hemoglobin analysis with transfusion and treatment history. A recent transfusion can alter hemoglobin fractions, and a low reticulocyte response during worsening anemia signals a different emergency.
Understand fetal hemoglobin
HbF does not participate in HbS polymer formation in the same way. Therapies that increase HbF can reduce sickling, but a laboratory rise is not the only treatment goal. Pain, acute chest syndrome, transfusion, organ injury, and quality of life remain clinically important.
Quick check
Lesson
Build Protection Around Functional Asplenia
Splenic dysfunction makes infection prevention a core treatment, not a background checklist. Vaccination, young-child antibiotic prophylaxis, fever response, and reliable access must work as one system.
- Functional asplenia
- Vaccines
- Penicillin
- Fever
- Access
- Teach-back
Reconcile pneumococcal, meningococcal, Hib, influenza, and routine products
Protect eligible young children according to current guidance
Treat possible invasive infection as urgent
Make emergency thresholds and contact routes explicit
Treat fever as urgent
Fever can be the first sign of invasive infection and may progress quickly. Patients and caregivers need a clear temperature threshold, contact route, and destination for urgent evaluation. Acute assessment commonly includes cultures and timely empiric antimicrobials according to local protocol.
Use the live CDC schedule
Keep routine vaccines current and apply risk-based pneumococcal, MenACWY, MenB, Hib, influenza, and other indications. Do not copy a fixed schedule from an older review book because products, ages, intervals, and prior-dose rules change.
Protect young children
CDC recommends daily penicillin or another prescribed antibiotic for children with SCD under age five. Verify the current patient-specific plan, allergy history, adherence, local protocol, and what must be true before prophylaxis changes.
Prevent other infections
Review travel, hepatitis exposure from transfusion, respiratory-virus prevention, dental health, and device or line risks. Newborn screening and early linkage to specialty care create the opportunity to begin protection before splenic function is lost.
Find access failure before infection
Missed vaccines, absent refills, transportation, pharmacy closures, insurance changes, health literacy, and prior traumatic encounters can defeat an otherwise correct plan. Record the barrier, intervention, and owner.
Quick check
Lesson
Treat Pain Quickly and Think Beyond Pain
Vaso-occlusive pain needs timely, respectful, individualized treatment. Simultaneously screen for acute chest syndrome, infection, stroke, sequestration, aplasia, priapism, pregnancy complications, and other diagnoses.
- VOC
- Analgesia
- Reassessment
- Fluids
- Oxygen
- Bias
Check chest, neurologic, infectious, abdominal, and genitourinary features
Use timely multimodal therapy with repeated reassessment
Correct hypoxemia and dehydration without causing fluid harm
Document response, discharge safety, and prevention follow-up
Begin with danger screening
Check vital signs, oxygenation, chest symptoms, fever, neurologic findings, severe headache, abdominal change, priapism, pregnancy, hydration, baseline hemoglobin, and atypical features. Pain location or behavior does not rule in or rule out a dangerous complication.
Deliver timely analgesia
Use the patient's effective regimen when available, severity-appropriate opioid and nonopioid options, and route matched to urgency. Reassess analgesia, sedation, respiration, nausea, pruritus, function, and need for another dose.
Use fluids and oxygen precisely
Correct clinically meaningful volume deficit while avoiding automatic large-volume hydration that can worsen pulmonary status. Give oxygen for hypoxemia rather than as a universal ritual. Encourage lung expansion according to the acute-care plan.
Do not transfuse uncomplicated pain
ASH Choosing Wisely advises against routine transfusion for uncomplicated pain crisis or chronic baseline anemia without an appropriate indication. Transfusion adds alloimmunization, reaction, viscosity, and iron risks without evidence that it relieves uncomplicated VOC pain.
Counter bias with process
Standardized rapid assessment, individualized plans, time-to-analgesia measurement, and neutral communication reduce the chance that stigma delays care. A urine drug screen or outward behavior is not a pain scale.
Quick check
Lesson
Recognize Sickle Cell Emergencies Before They Declare Themselves
Acute chest syndrome, stroke, sepsis, splenic sequestration, aplastic crisis, and ischemic priapism can evolve quickly. The safest response is syndrome recognition, parallel stabilization, and early specialty escalation.
- Acute chest
- Stroke
- Sepsis
- Sequestration
- Aplasia
- Priapism
Escalate oxygenation, antibiotics, respiratory support, and transfusion decisions
Activate imaging and exchange-transfusion expertise
Treat acute pooling, anemia, and shock
Do not normalize time-sensitive complications
Escalate acute chest syndrome
A new pulmonary infiltrate plus compatible respiratory or systemic features can reflect infection, infarction, fat embolism, hypoventilation, or multiple mechanisms. Track oxygenation and work of breathing, treat likely infection, support ventilation, control pain, and involve transfusion expertise early.
Treat neurologic change as stroke
New weakness, speech change, facial asymmetry, seizure, severe focal headache, altered consciousness, or other acute deficit requires immediate stroke evaluation. Coordinate imaging and urgent sickle-cell transfusion strategy; do not let a normal prior visit delay action.
Separate sequestration from aplasia
Splenic sequestration causes acute pooling, splenic enlargement, falling hemoglobin, and possible shock. Aplastic crisis produces severe anemia with an inappropriately low reticulocyte response, often after parvovirus exposure. Both need urgent evaluation but require different reasoning.
Protect time in priapism
Ischemic priapism lasting several hours risks permanent injury and needs urgent urologic treatment. Recurrent shorter events also need a preventive plan. Medication review and hydration do not replace timely procedural care when ischemia persists.
Use transfusion by syndrome
Severe acute chest syndrome and acute neurologic events may require exchange transfusion, while other conditions may use simple transfusion. Hemoglobin, HbS burden, viscosity, speed, access, and expert availability shape the method.
Quick check
Lesson
Use Hydroxyurea as a Monitored System
Hydroxyurea can raise HbF and reduce painful events, acute chest syndrome, hospitalization, and transfusion burden. Safe benefit depends on current indication, reliable exposure, count-guided dosing, and reproductive counseling.
- HbF induction
- Myelosuppression
- Titration
- Adherence
- Pregnancy
- Handling
Reduce the fraction of hemoglobin available to sickle
Use product and protocol-specific dose rules
Interrupt and recover rather than escalating through toxicity
Daily use, laboratories, handling, and reproductive planning belong together
Match evidence and indication
Discuss hydroxyurea broadly with eligible patients using current guidelines and product labeling. Siklos is FDA labeled for pediatric patients age two and older with sickle cell anemia and recurrent moderate to severe painful crises, while specialist protocols address additional populations.
Titrate through counts, not habit
Starting dose, escalation, maximum dose, renal adjustment, and monitoring differ by product, age, organ function, and protocol. Monitor CBC with differential and reticulocytes, and interrupt for clinically important cytopenia according to the selected protocol.
Measure clinical response
MCV and HbF trends can support exposure assessment, but fewer VOCs, acute chest events, admissions, and transfusions are more meaningful. Apparent failure requires an adherence, access, dose, and competing-disease audit before abandonment.
Counsel without stigma
Explain purpose, daily administration, missed-dose plan, laboratory visits, safe handling, reproductive risks, pregnancy planning, and when to call. Avoid presenting hydroxyurea only as a cancer drug because that framing can obscure its established SCD benefit.
Plan interruption and recovery
When counts cross protocol thresholds, hold treatment, evaluate the cause, monitor recovery, and restart at the defined dose. Do not escalate through myelosuppression or let temporary interruption become unreviewed permanent discontinuation.
Quick check
Lesson
Keep the Disease-Modifying List Current
A correct 2023 medication list became unsafe after voxelotor withdrawal. Current care separates hydroxyurea, L-glutamine, and US-labeled crizanlizumab from a drug that should no longer be initiated.
- L-glutamine
- Crizanlizumab
- P-selectin
- Voxelotor
- Withdrawal
- Shared decisions
Offer an oral preventive option to eligible patients
Crizanlizumab remains US labeled for VOC reduction from age 16
FDA withdrawal means historical content must not guide initiation
Match goals, route, evidence, access, and patient preference
Use L-glutamine for its defined role
Endari is an oral product used to reduce acute complications in eligible patients. Confirm current age and indication, product preparation, twice-daily burden, tolerability, adherence, and event trajectory. It is preventive, not curative.
Locate crizanlizumab correctly
Adakveo blocks P-selectin and remains FDA labeled in the United States to reduce VOC frequency in patients age 16 and older. Confirm current labeling, infusion schedule, response, and infusion-related reactions. Regulatory decisions outside the United States do not automatically change US status.
Retire voxelotor
Pfizer voluntarily withdrew Oxbryta in September 2024 after the FDA concluded its benefit no longer outweighed risk, including concern for higher VOC and fatal events. Do not initiate it. Identify any historical use and coordinate a safe transition with hematology.
Do not stack therapies automatically
Combination decisions depend on disease burden, prior response, administration route, monitoring, evidence, cost, access, and patient preference. More products do not guarantee more benefit, and every treatment needs a measurable objective.
Timestamp medication knowledge
FDA pages and older textbooks can retain stale therapy lists. Record the label or withdrawal source and review date whenever regulatory status changes the recommendation.
Quick check
Lesson
Treat Transfusion as Precision Therapy
Transfusion can prevent or treat severe complications, but every exposure can create alloantibodies, delayed hemolysis, hyperviscosity, volume burden, and iron overload. The indication, product, method, target, and follow-up must be explicit.
- Antigen profile
- Simple transfusion
- Exchange
- Alloimmunization
- Hyperhemolysis
- Iron overload
Preserve genotype, phenotype, antibodies, and reaction history
Balance oxygen delivery, HbS reduction, viscosity, and iron
Treat post-transfusion pain and anemia as a possible reaction
Use exposure history, MRI assessment, and product-specific chelation
Profile before the emergency
Obtain extended red cell antigen profiling, preferably genotype-based when appropriate, before transfusion exposure or as early as possible. Preserve every historical antibody because it may later become undetectable while still affecting compatibility.
Choose simple or exchange
Simple transfusion raises hemoglobin and oxygen capacity but can increase viscosity and net iron. Exchange lowers HbS more directly and can limit net iron but requires equipment, access, expertise, and procedure monitoring. Match method to the clinical syndrome.
Recognize delayed hemolysis
Pain, jaundice, dark urine, fever, or hemoglobin falling below the pretransfusion value days to weeks later can indicate delayed hemolytic reaction or hyperhemolysis. Compare counts, reticulocytes, hemolysis markers, DAT, antibody testing, and hemoglobin fractions with expert support.
Do not reflexively retransfuse
Additional blood during hyperhemolysis can worsen destruction. Unless anemia is life-threatening, involve transfusion medicine and hematology before further exposure. Severe cases may require immunomodulatory treatment according to expert guidance.
Measure iron beyond ferritin
Chronic transfusion requires cumulative exposure review and organ-sensitive assessment, often including MRI-based liver iron. Ferritin trends help but are affected by inflammation. Select chelation and monitoring from the exact product, organ function, burden, and adherence.
Quick check
Lesson
Protect Organs Before Symptoms Become Irreversible
SCD affects brain, kidney, lung, heart, bone, eye, liver, reproductive health, and mental health. Surveillance should be age, genotype, history, symptom, and guideline specific rather than a generic annual panel.
- TCD
- Kidney
- Cardiopulmonary
- Retinopathy
- Reproduction
- Mental health
Prevent overt and silent cerebrovascular disease
Look beyond a reassuring low creatinine
Use targeted evaluation instead of indiscriminate advanced screening
Coordinate pregnancy, contraception, and fertility decisions
Prevent cerebrovascular injury
Use age and genotype-appropriate transcranial Doppler screening and chronic transfusion prevention for qualifying children. Prior stroke, silent infarct, cognitive change, school difficulty, seizure, or new neurologic symptoms changes the pathway.
Find kidney injury early
Albuminuria, hyperfiltration, impaired concentrating ability, hematuria, and progressive CKD can occur. Low muscle mass or hyperfiltration can make serum creatinine falsely reassuring. Trend blood pressure, urine albumin, filtration estimates, potassium, and medication exposure.
Let symptoms guide cardiopulmonary testing
ASH does not support indiscriminate advanced screening for pulmonary hypertension, lung function abnormality, or sleep disorders in every asymptomatic patient. Dyspnea, hypoxemia, chest pain, exercise limitation, syncope, sleep symptoms, or recurrent acute chest syndrome should trigger targeted evaluation.
Individualize reproductive care
Use coordinated high-risk pregnancy and hematology care. Review disease control, organ status, medicines, transfusion history, thrombosis, fertility, and fetal risk. Contraception should follow current medical eligibility and patient factors rather than an old universal ban on estrogen.
Include quality of life
Chronic pain, depression, anxiety, sleep disturbance, cognitive effects, school or work disruption, and treatment burden are clinical outcomes. Screen, validate, treat, and connect patients with social and behavioral support.
Quick check
Lesson
Compare Three Potentially Curative Paths
Allogeneic transplant, Casgevy, and Lyfgenia can transform disease trajectory, but each requires specialized selection, intensive conditioning, fertility discussion, acute risk management, and long-term surveillance.
- Allogeneic HSCT
- Casgevy
- BCL11A
- Lyfgenia
- Conditioning
- Long-term follow-up
Balance donor, graft, organ, fertility, and immune risks
Disrupt the erythroid BCL11A enhancer to restore fetal hemoglobin
Deliver modified beta-globin with a lentiviral vector
Conditioning and delayed product risks persist beyond infusion
Understand allogeneic transplant
Donor-derived hematopoiesis can replace the sickle-producing marrow. Outcomes depend on donor, age, organ damage, regimen, graft failure, graft-versus-host disease, infection, fertility, and center expertise. Shared decision making should begin before irreversible organ injury when possible.
Understand Casgevy
Exagamglogene autotemcel uses CRISPR/Cas9 to edit the erythroid BCL11A enhancer in autologous CD34-positive cells, increasing HbF after reinfusion. In July 2026, FDA expanded the SCD indication to patients age two and older with recurrent VOCs.
Understand Lyfgenia
Lovotibeglogene autotemcel uses a lentiviral vector to add a modified beta-globin gene to autologous cells. It is FDA indicated from age 12 for patients with a history of vaso-occlusive events and carries a serious hematologic malignancy and insertional oncogenesis warning.
Do not hide conditioning
Autologous source avoids donor matching and graft-versus-host disease, but gene therapy still requires collection, manufacturing, myeloablative conditioning, hospitalization, engraftment, infection protection, fertility planning, and prolonged follow-up.
Make access part of consent
Authorized-center travel, coverage, caregiver support, time away from school or work, fertility preservation, uncertainty, and lifelong surveillance shape whether a technically eligible therapy is feasible and acceptable.
Quick check
Lesson
Make Care Travel With the Patient
SCD care crosses home, pharmacy, clinic, emergency department, infusion center, blood bank, hospital, school, work, obstetrics, and transplant programs. Continuity must be designed rather than assumed.
- Individualized plan
- Transitions
- Adherence
- Equity
- Emergency record
- Ownership
Find bleeding, suppression, hemolysis, depletion, and absorption effects
Use teach back for products, schedules, interactions, and danger signs
Time CBC and cause-specific studies to the expected response
Act on unexplained anemia, abnormal smear, pancytopenia, hemolysis, or failure
Preserve antibodies, effective analgesia, complications, and preferences
Establish adult care before pediatric care closes
Audit delays and solve barriers without blame
Assign every laboratory, vaccine, referral, and response review
Preserve the clinical baseline
Record genotype, usual hemoglobin and reticulocytes, organ history, prior acute chest or stroke, effective pain plan, venous access, transfusion antigens and antibodies, reactions, disease-modifying therapy, allergies, and key specialists.
Build transitions before transfer
Adult-care transition requires knowledge, self-management, medication access, insurance, records, appointments, and a receiving team. Confirm the first adult visit and emergency plan before pediatric services close.
Audit adherence without blame
Use neutral questions, refill history, laboratory patterns, clinical events, and patient goals to identify burden, adverse effects, cost, trauma, transportation, stigma, mistrust, or competing priorities. Solve the actual barrier rather than assigning a label.
Measure equity
Track time to analgesia, repeat assessment, access to disease modification, vaccination, transfusion matching, organ screening, fertility counseling, transplant evaluation, and gene-therapy referral. Variation by race, age, language, geography, or coverage is a quality signal.
Close every loop
For each medicine, vaccine, laboratory, referral, or acute-care change, state the target, date, failure rule, danger sign, and person responsible for review. The next encounter should begin with what happened to the last plan.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 160 question bank.
Each attempt draws a fresh set and rearranges the answer choices.